The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 1 June 2024 | Viewed by 1252
Special Issue Editor
Interests: DNA methylation; cancer invasion and metastasis in breast and pancreatic cancers; carcinoma-associated fibroblasts; epithelial–mesenchymal transition; AKT signaling pathway; tumor microenvironment and immune evasion
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the Special Issue "The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion" (https://www.mdpi.com/journal/cancers/special_issues/TMMIE).
It has been widely recognized that the complex interplay between immunity and cancer determines whether cancer cells will survive or be destroyed. The battle between tumoricidal and tumor-promoting activity relies on the extent to which the antitumor immune response is exerted. In general, immune evasive mechanisms adapted by cancers encompass the downregulation of antigen presentations or recognition, a lack of immune effector cells, the obstruction of antitumor immune cell maturation, the accumulation of immunosuppressive cells, the production of inhibitory cytokines, chemokines or ligands/receptors, the establishment of a hypoxic tumor microenvironment, the development of cancer-promoting metabolisms, and the upregulation of immune checkpoint modulators. As such, restoring or stimulating tumoricidal effects, in conjunction with surgical resection and chemo- or radiation-mediated, hormone-based, kinase-targeted, DNA repair-disrupted, small molecule inhibitor-mediated, signal transduction pathway-modified, aberrant epigenome-reverted, and cytokine-involved treatments, may spark promising therapeutic regimens to eradicate fatal cancers. This Special Issue welcomes papers outlining mechanisms of immune escape or depicting strategies for boosting immune surveillance, compatible with additional non-immune interventions to eradicate human cancers.
Dr. Huey-Jen Lin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CD8+ tumor-infiltrating lymphocytes
- cytotoxic T lymphocytes -associated protein 4
- dendritic cells
- immune evasion
- hypoxia-inducible factors
- myeloid-derived suppressor cells
- natural killer
- programmed death receptor and ligand
- regulatory T cells
- tumor-associated macrophages
- tumor microenvironment
